NCT06083844View on ClinicalTrials.gov

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Ovarian Cancer
Interventions
DRUG

Pembrolizumab

Given by IV (vein)

DRUG

Bevacizumab

Given by IV (vein)

DRUG

Cyclophosphamide

Given by mouth

Trial Locations (2)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER